Availability of suPAR in emergency departments may improve risk stratification

Sun Jan 27 2019

New abstract published in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine;

“Availability of suPAR in emergency departments may improve risk stratification: A secondary analysis of the TRIAGE III trial” by Schultz M et al.

Results:

“The study included 4420 patients with an available triage category and suPAR measurement.
suPAR was significantly better in predicting mortality than triage; AUC 0.85 vs. 0.71, P < 0.001.

Combining suPAR and triage yielded an AUC of 0.87.
The Youden’s cut-off of suPAR was 5.9 ng/mL and reclassified triage using this value resulted in a more accurate risk stratification regarding hospital admission and mortality.

Conclusion:

“Addition of the prognostic biomarker suPAR to triage potentially improves prediction of seven-day mortality in the emergency department.
Measurement of suPAR in relation to the triage process may allow a more accurate identification of ED patients at high and low risk of short-term mortality and enable a subsequent reclassification of patients.”

pdfLink to publication here

900+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates